Clinical trials: Migraine Prophylaxis
Vestibular Migraine, Dizziness
Chinese Real-world Study of Treatment of Vestibular Migraine
Vestibular migraine is a phenotype of migraine, characterized by more prominent vertigo symptoms compared to headache. Treatments for VM are mainly divided into two categories: acute treatment and preventive treatment.
- Conditions
- Vestibular Migraine, Dizziness, Vertigo
- Trial name
- NCT07203248
- Testing
- CGRP R Inhibitor; CGRP Inhibitor, none-CGRP
- Volunteers
- 2,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Episodic Migraine, Prophylaxis
The Role of Left Prefrontal Transcranial Magnetic Stimulation in Episodic Migraine Prophylaxis
The aim of the study was to examine the prophylactic role of repetitive transcranial magnetic stimulation (rTMS) on the frequency, and severity of migraine attacks in episodic migraineurs who failed medical treatment.
- Trial name
- NCT04031781
- Testing
- repetitive transcranial magnetic stimulation (rTMS) 100% motor threshold, repetitive transcranial magnetic stimulation (rTMS) 50% motor threshold
- Volunteers
- 33 people
- Sponsor
- Ain Shams University
Migraine
Efficacy and Safety of Oral NBP Soft Capsules for the Prevention of Episode Migraine Attacks in Adult Migraine Patients
This is a multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of oral butylphthalide soft capsules for the prophylactic treatment of migraine in adults.
- Trial name
- ENERGY (NCT06968429)
- Testing
- NBP Softgel Capsules
- Volunteers
- 500 people
- Sponsor
- Chinese PLA General Hospital
Episodic Migraine
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- TANDEM (NCT05264129)
- Testing
- Atogepant, Ubrogepant
- Where
- 37 sites in United States
- Volunteers
- 263 people
- Sponsor
- AbbVie
Migraine
Intra-Nasal Mechanical Stimulation (INMEST) as a Potential Preventative Treatment for Migraine
This is a prospective, randomized, open-label, delayed-start clinical investigation evaluating the safety and efficacy of the Walther System, a Class IIa investigational medical device delivering intra-nasal mechanical…
- Trial name
- A-MI-01 (NCT07279623)
- Testing
- INMEST-treatment
- Where
- Sweden
- Volunteers
- 110 people
- Sponsor
- Abilion Medical Systems AB
Menstrual Migraines, Menstrual Bleeding
Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives.
This study will examine the combined effects of a continuous oral contraceptive (OC) regimen with supplemental estradiol therapy on headache severity and occurrence in subjects with documented Menstrually Associated Migraines…
- Conditions
- Menstrual Migraines, Menstrual Bleeding, Menstrual Spotting
- Trial name
- Estradiol/MAM (NCT01251263)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Scott and White Hospital & Clinic
Adolescent Migraine
Evaluation of Efficacy and Safety of add-on Alpha-lipoic Acid on Migraine Prophylaxis in Adolescent Population
Migraine causes a substantial impact on the physical and mental health of a child and it is a major cause for time-off school leading to impaired academic performance.
- Trial name
- NCT04064814
- Testing
- Flunarizine 5mg, Alpha lipoic acid 300mg
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Migraine
Desvenlafaxine for Preventive Treatment of Frequent Migraines
To evaluate whether Desvenlafaxine can reduce the frequency and severity of migraine attacks in patients.
- Trial name
- NCT07385755
- Testing
- Desvenlafaxine
- Where
- China
- Volunteers
- 440 people
- Sponsor
- Tongji Hospital
Chronic Migraine, Episodic Migraine
A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
This study will evaluate the long-term safety, efficacy and tolerability of atogepant 60 mg daily for the prevention of migraine in Japanese participants with chronic (CM) or episodic migraine (EM).
- Trial name
- JPN ATO OLE (NCT04437433)
- Testing
- Atogepant 60 mg
- Where
- 24 sites in Japan
- Volunteers
- 186 people
- Sponsor
- AbbVie
Migraine Disorders
Lippia Alba for Migraine Prophylaxis and Treatment
Abstract Background: There is no universally accepted and effective prophylaxis of migraine headache episodes. Thus the investigators aimed to investigate the effects of Lippia alba (Mill.) N. E.
- Trial name
- NCT01259947
- Testing
- Lippia alba (Mill.) N. E. Brown ethanolic extract
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Fabio Carmona
Intervention
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
This study will assess the efficacy of a neuromodulation device for the treatment of episodic migraine headache.
- Trial name
- NCT02991430
- Testing
- active neuromodulation for episodic migraine headache
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Scion NeuroStim
Chronic Migraine
Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.
- Trial name
- NCT03855137
- Testing
- Atogepant 30 mg, Atogepant 60 mg
- Where
- 150 sites in United States, Australia and 15 more
- Volunteers
- 778 people
- Sponsor
- Allergan
Chronic Migraine, Headache
Open Label, 6-month Study for High Frequency and Chronic Migraine,
This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs/month) requiring preventive treatment. Enrolled patients will receive DAX administered subcutaneously using an established, published…
- Trial name
- NCT06133491
- Testing
- Daxibotulinumtonix A
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Ki Health Partners. LLC
Migraine, Episodic Migraine
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Randomized study of two digital therapeutics for the prevention of episodic migraine
- Conditions
- Migraine, Episodic Migraine, Headache, Headache, Migraine
- Trial name
- ReMMi-D (NCT05853900)
- Testing
- ReMMi-D Digital Therapeutic
- Where
- United States
- Volunteers
- 568 people
- Sponsor
- Click Therapeutics, Inc.
Episodic Migraine
Prophylactic Treatment With Atorvastatin for Episodic Migraine.
The main objective of this study is to see whether the favorable preventative effect of Atorvastatin 40mg per day in episodic migraine, that was found previously in three smaller randomized controlled cross-over studies, can be…
- Trial name
- EStatinMig (NCT06248671)
- Testing
- Atorvastatin 40mg, Atorvastatin 20mg
- Where
- 6 sites in Norway
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- St. Olavs Hospital
Episodic Migraine, Chronic Migraine
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
- Trial name
- NCT04686136
- Testing
- Atogepant 60 mg
- Where
- 116 sites in United States, Canada and 12 more
- Volunteers
- 596 people
- Sponsor
- AbbVie
Migraine Headaches
A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine
The purpose of this study is to evaluate whether RWJ-333369 is a safe and effective treatment in reducing the number of migraine headaches when added to a person's usual medications for acute migraine headache relief.
- Trial name
- NCT00109083
- Testing
- RWJ-333369
- Where
- 25 sites in United States
- Volunteers
- 300 people
- Sponsor
- SK Life Science, Inc.
Migraine
Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with episodic migraine.
- Trial name
- EVOLVE-1 (NCT02614183)
- Testing
- Galcanezumab
- Where
- 95 sites in United States, Canada and 1 more
- Volunteers
- 862 people
- Sponsor
- Eli Lilly and Company
Migraine
Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- PRACTICE (NCT07690215)
- Volunteers
- 200 people
- Sponsor
- AbbVie
Migraine Headache
Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine.
Migraine is one of the three most disabling diseases worldwide. Constituted by recurrent episodes of headache, characterized by unilateral location, throbbing character, moderate or severe intensity, worsening with physical…
- Trial name
- NCT04698525
- Testing
- Valproate Sodium, Memantine
- Where
- Mexico
- Volunteers
- 33 people
- Sponsor
- Universidad Autonoma de San Luis Potosí